Safety update of etanercept treatment for moderate to severe plaque psoriasis
A Campanati, F Diotallevi, E Martina… - Expert Opinion on …, 2020 - Taylor & Francis
Introduction: Conventional topical therapies and disease-modifying anti-rheumatic drugs
(DMARDs) for patients with psoriasis are often linked to inadequate outcomes and risk of …
(DMARDs) for patients with psoriasis are often linked to inadequate outcomes and risk of …
Safety update of etanercept treatment for moderate to severe plaque psoriasis
A Campanati, F Diotallevi, E Martina… - Expert opinion on …, 2020 - pubmed.ncbi.nlm.nih.gov
Introduction: Conventional topical therapies and disease-modifying anti-rheumatic drugs
(DMARDs) for patients with psoriasis are often linked to inadequate outcomes and risk of …
(DMARDs) for patients with psoriasis are often linked to inadequate outcomes and risk of …
Safety update of etanercept treatment for moderate to severe plaque psoriasis
A Campanati, F Diotallevi, E Martina… - EXPERT OPINION ON …, 2020 - iris.univpm.it
Introduction: Conventional topical therapies and disease-modifying anti-rheumatic drugs
(DMARDs) for patients with psoriasis are often linked to inadequate outcomes and risk of …
(DMARDs) for patients with psoriasis are often linked to inadequate outcomes and risk of …
Safety update of etanercept treatment for moderate to severe plaque psoriasis.
A Campanati, F Diotallevi, E Martina… - Expert Opinion on …, 2020 - europepmc.org
Introduction: Conventional topical therapies and disease-modifying anti-rheumatic drugs
(DMARDs) for patients with psoriasis are often linked to inadequate outcomes and risk of …
(DMARDs) for patients with psoriasis are often linked to inadequate outcomes and risk of …